Oral Estradiol Plateau and Non-Response Troubleshooting

How the label frames dose adjustment

The estradiol tablet label is written in terms of symptom control, not serum levels. It directs that the lowest dose and regimen that will control symptoms be chosen, that the usual initial dosage range is 1 to 2 mg of estradiol daily adjusted as necessary to control presenting symptoms, and that the minimal effective dose for maintenance be determined by titration [1]. Administration is meant to be cyclic, for example 3 weeks on and 1 week off [1].

Reassessment is scheduled rather than triggered by a lab value: patients should be reevaluated periodically as clinically appropriate, for example at 3-month to 6-month intervals, and attempts to discontinue or taper should be made at 3-month to 6-month intervals [1].

How is the dose guided?

The oral tablet label describes adjusting the dose to control symptoms [1], and the Climara patch label states that dosage adjustment should be guided by the clinical response [2].

The Climara label does mention a serum estradiol level, but as an enrollment criterion rather than a treatment goal: the patch trials enrolled postmenopausal women with a serum estradiol level of less than 20 pg/mL and at least five moderate to severe hot flushes per week, or 15 flushes per week of any severity, at baseline [2].

Why the route changes what reaches the blood

Oral estradiol passes through the liver before it reaches the rest of the body. The label describes estradiol being converted reversibly to estrone, with both able to be converted to estriol, mainly in the liver, along with enterohepatic recirculation and a circulating reservoir of estrone sulfate [1]. Estradiol itself is substantially more potent at the estrogen receptor than its metabolites estrone and estriol [1].

The Climara label states that systemic availability of estradiol after transdermal use is about 20 times higher than after oral use because there is no first-pass metabolism, and that the patch delivers estradiol steadily over 7 days [2]. That is a difference in how much drug reaches the circulation; it is not a head-to-head demonstration that a patch relieves symptoms better.

Medicines that can reduce the effect of oral estradiol

Estrogens are metabolized partly by CYP3A4, so inducers and inhibitors of that enzyme can change estradiol concentrations [1][2]. The label lists St. John's wort, phenobarbital, carbamazepine and rifampin as inducers that may reduce plasma concentrations of estrogens, possibly resulting in a decrease in therapeutic effects and/or changes in the uterine bleeding profile [1]. It lists erythromycin, clarithromycin, ketoconazole, itraconazole, ritonavir and grapefruit juice as inhibitors that may increase concentrations and cause side effects [1][2].

Options when symptoms persist on oral tablets

Dose adjustment. The oral tablet label describes adjusting the dose according to symptom control and directs use of the lowest effective dose for the shortest duration consistent with treatment goals [1]. The WHI findings came from specific oral conjugated-estrogen regimens, not estradiol tablets; the oral label says other doses, combinations and dosage forms were not studied in those trials and, in the absence of comparable data, the risks should be assumed to be similar [1].

Cover the uterus. The oral label says that when estrogen is prescribed for a postmenopausal woman with a uterus, a progestin should also be initiated to reduce the risk of endometrial cancer, and that a woman without a uterus does not need one [1]. The labels state that unopposed estrogen raises endometrial cancer risk and that persistent or recurring abnormal genital bleeding calls for adequate diagnostic measures, including endometrial sampling when indicated [1][2].

Match the product to the symptom. When estrogen is prescribed solely for symptoms of vulvar and vaginal atrophy, both the tablet and patch labels say topical vaginal products should be considered first [1][2]. This matters when dryness or irritation is the symptom that has not responded while hot flushes have.

Change the route. The Climara label says to start at 0.025 mg per day applied once weekly to the lower abdomen below the navel or the upper buttock, not on the breasts, with adjustment based on clinical response and attempts to taper or discontinue at 3- to 6-month intervals [2]. The Vivelle-Dot label starts at 0.0375 mg per day applied twice weekly [4].

Clot risk and switching to a patch

The strongest comparative data on route are observational. The ESTHER case-control study, conducted in France between 1999 and 2005, compared 271 women aged 45 to 70 with a first idiopathic venous thromboembolism against 610 matched controls: the adjusted odds ratio for VTE in current users was 4.2 (95% CI 1.5 to 11.6) for oral estrogen and 0.9 (95% CI 0.4 to 2.1) for transdermal estrogen [5]. A 2008 BMJ systematic review of eight observational studies and nine randomized trials found, in the observational studies, a pooled odds ratio for a first VTE of 2.5 (1.9 to 3.4) with oral estrogen and 1.2 (0.9 to 1.7) with transdermal, with the oral risk highest in the first year of use at 4.0 (2.9 to 5.7) [6].

These are not randomized comparisons of the two routes, and the patch labeling does not treat transdermal use as clot-free: the Climara label carries a boxed warning, lists active DVT or PE or a history of these as a contraindication, notes that only daily oral conjugated estrogens 0.625 mg were studied in the WHI estrogen-alone substudy so the relevance of those findings to other routes is not known, and says that, if feasible, estrogens should be discontinued at least 4 to 6 weeks before surgery associated with increased thromboembolism risk or during prolonged immobilization [2].

Compounded estradiol when tablets seem not to work

Compounded estradiol is not FDA-approved. FDA does not verify the safety, effectiveness or quality of compounded drugs before they are marketed, and says compounded drugs should only be used when a patient's needs cannot be met by an FDA-approved drug; FDA-approved estradiol tablets and patches exist [3].